Phospholipase A2 receptor antibody mediated membranous nephropathy associated with cemiplimab

Background: Immune checkpoint inhibitors (ICI) are a fast growing therapy used in several types of malignancies. The majority immune related adverse events observed the kidney due to acute interstitial nephritis. Glomerular diseases although less common have also been described. Case Presentation: We present case phospholipase A2 receptor positive membranous nephropathy triggered by ICI cemiplimab (PD1 inhibitor) 88 year old man with no prior history proteinuria or glomerular disease. patient responded steroid monotherapy rapid clinical and immunological remission. Conclusion: While patients undergoing warrant close monitoring systemic events, physicians should remain vigilant obtain biopsy if clinically indicated.